Planning advanced therapy trials for Huntington’s Disease: ethical considerations

Towns, Cindy, Ballantyne, Angela, Konstatinova, Pavlina, Drew, Cheney ORCID: https://orcid.org/0000-0002-4397-6252 and Rosser, Anne ORCID: https://orcid.org/0000-0002-4716-4753 2026. Planning advanced therapy trials for Huntington’s Disease: ethical considerations. Molecular Therapy 10.1016/j.ymthe.2026.09.035

Full text not available from this repository.

Abstract

Huntington’s Disease (HD) is a relentlessly progressive genetic disorder characterised by cognitive, behavioural and physical impairments. The lack of effective treatments, early onset of symptoms and high rates of suicide reflect a disease of significant human suffering. The ethical imperative to pursue disease modifying treatments with gene and stem cell therapies - collectively referred to as advanced therapeutic medicinal products (ATMPs) - is therefore sound. Recent gene therapy trials have generated international attention and widespread hope in the HD community, however gene and stem cell therapies are fraught with ethical challenges and complexity. Genetic discrimination, trial design challenges (especially the use of surgical placebos) and the risk for therapeutic misconception need careful consideration whilst broader concerns relating to justice and equity must be recognised by researchers and funders alike. This paper will provide those involved in gene therapy trials and other advanced therapy research a comprehensive overview of the ethical issues.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Medicine Research Institutes & Centres > Centre for Trials Research (CNTRR)
Publisher:	Cell Press
ISSN:	1525-0016
Last Modified:	05 Oct 2026 10:00
URI:	https://orca.cardiff.ac.uk/id/eprint/189979

Actions (repository staff only)

Edit Item